The Role of Pre-Clinical Bleomycin Models in IPF Drug Development
In this article, TherapeutAix has come together with one of our partners, OracleBio, a provider of Quantitative Digital Pathology services…
Reflections from ECM2022, Copenhagen, July 2022
The Extracellular Matrix Pharmacology Symposium 2022, aka ECM2022, took place in Copenhagen a couple of weeks ago. The focus of…
Join TherapeutAix at the SMR Meeting ‘Innovative New Pharma & Biotech Partnerships’
Darcey Black, Translational Director at TherapeutAix, will be co-organising and attending the ‘Innovative New Pharma and Biotech Partnerships: How is…
International NASH Day 2022 – Enabling therapies for patients
Non-alcoholic steatohepatitis, or NASH, remains a disease with no approved therapeutics. And it’s been a tough area for drug development,…
TherapeutAix to attend Fraunhofer ‘Models of Lung Disease’ Seminar
TherapeutAix will be attending the 20th Fraunhofer Seminar ‘Models of Lung Disease’ on 22-24 June at the CRC Hannover in…
